One of these stocks was pushed higher after it revealed who will next sit in the CEO's chair.
News & Analysis: Ra Pharmaceuticals, Inc. Common Stock
Shares make a triple-digit jump after the company announces that it has agreed to be acquired. Here's what investors need to know.
Historically, the underlying cause of ALS has evaded researchers, except in rare genetic cases. But more light has been shone on the disease and the potential of new avenues for drug intervention.
Find out which of these stocks got a buyout bid.
Investors are cheering for successful results from a mid-stage trial with the company's lead candidate.
"Positive" phase 2 data for RA101495 SC wasn't positive enough.
Investors find fault in Ra's phase 2 initial data for its lead drug.